文献速递MDS 与骨髓增殖性肿瘤白血病

骨髓增殖性肿瘤患者疾病转化与第二原发实体瘤风险

Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
PubMed 文献 · Blood Adv · 2019-01-01

该研究基于韩国全国医保数据,分析7454例2008至2016年新诊断的BCR-ABL1阴性骨髓增殖性肿瘤(MPN)患者。结果显示,原发性骨髓纤维化(PMF)患者8年继发性急性髓系白血病(SAML)累积发生率为21.4%,真性红细胞增多症(PV)或原发性血小板增多症(ET)患者8年第二原发实体瘤累积发生率约14%,MPN患者第二原发实体瘤风险为韩国一般人群的2倍。

要点

  • PMF患者8年SAML累积发生率为21.4%,ET/PV患者转化罕见。
  • PV或ET患者8年第二原发实体瘤累积发生率约14%。
  • MPN患者第二原发实体瘤风险为一般人群的2倍,涉肾、前列腺、脑、肝、肺。

核心结论

  • ET或PV患者转化为继发性骨髓纤维化(SMF)或SAML罕见,但PMF患者SAML常见。
  • 韩国MPN患者第二原发实体瘤风险显著高于一般人群,尤其肾、前列腺、脑、肝和肺癌。

研究设计与样本

  • 基于韩国全国医保索赔数据的回顾性队列研究,纳入2008至2016年新诊断的7454例BCR-ABL1阴性MPN患者。

主要发现

  • PMF患者8年SAML累积发生率为21.4%。
  • PV或ET患者8年第二原发实体瘤累积发生率约为14%。
  • MPN患者发生第二原发实体瘤的风险为韩国一般人群的2倍。
  • 与PMF患者相比,SMF患者总生存相似但发生SAML的风险更低。
  • 中位随访16.2个月期间,使用芦可替尼未增加B细胞淋巴瘤风险。

临床怎么用

  • 对PMF患者应警惕SAML发生,对ET/PV患者需关注第二原发实体瘤筛查。
  • MPN患者第二原发实体瘤风险升高,尤其应关注肾、前列腺、脑、肝和肺癌筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to elucidate patterns of disease transformation to secondary myelofibrosis (SMF) or secondary acute myeloid leukemia (SAML) and the development of second primary malignancies in South Korean patients with BCR-ABL1-negative myeloproliferative neoplasms (MPNs). By using nationwide public health care insurance claims data, we identified and analyzed 7454 patients with MPNs who were newly diagnosed with essential thrombocythemia (ET), polycythemia vera (PV), or primary myelofibrosis (PMF) from 2008 to 2016 and used the data to appropriately trace the disease course. Transformation to SMF or SAML was rare in patients with ET and PV, but patients with PMF had an 8-year cumulative incidence of SAML of 21.4%. Patients with PV or ET had an 8-year cumulative incidence of second primary solid tumors of ∼14%. Patients with MPNs had a 2 times higher risk of developing second primary solid tumors than that of the general South Korean population. Compared with patients with PMF, patients with SMF had a similar overall survival with a lower risk of developing SAML. The use of ruxolitinib did not increase the risk of developing B-cell lymphoma over a median follow-up period of 16.2 months. Disease transformation to SMF or SAML was rare in patients with ET or PV, but SAML was common in patients with PMF. South Korean patients with MPNs had a significantly higher risk of developing second primary solid tumors than that of the general population, particularly for kidney, prostate, brain, liver, and lung cancers.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hong J, Lee JH, Byun JM, et al. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. Blood Adv. 2019. PMID: 31765478. doi:10.1182/bloodadvances.2019000655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。